Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02354404
Recruitment Status : Completed
First Posted : February 3, 2015
Last Update Posted : December 5, 2017
Sponsor:
Collaborators:
US Military HIV Research Program
The Emmes Company, LLC
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:

Phase Ib study in 90 healthy adults,18 years to 65 years of age, to evaluate the safety, tolerability and immunogenicity of the VRC-EBOADC069-00-VP (cAd3-EBO) and VRC-EBOADC076-00-VP (cAd3-EBOZ) investigational Ebola vaccines in Part 1 and boosting with the VRC-EBOMVA079-00-VP (MVA-EbolaZ) investigational Ebola vaccine in Part 2.

Part 1: Randomizations to cAd3-EBO or cAd3-EBOZ at two different dose levels within Group 1 will include at least 60 volunteers who have never received an investigational Ebola vaccine. Randomizations to cAd3-EBO at two different dose levels within Group 2 may include up to 30 eligible participants who previously participated in the RV247 vaccine clinical trial and received the investigational VRC-EBODNA023-00-VP (Ebola DNA WT) vaccine.

Part 2: Participants in Part 1 may receive a booster vaccination with the MVA-EbolaZ vaccine at the same dose level.


Condition or disease Intervention/treatment Phase
Hemorrhagic Fever, Ebola Biological: cAd3-EBOZ Biological: cAd3-EBO Biological: MVA-EbolaZ Phase 1

Detailed Description:

Study Design: This Phase 1b, open-label study to examine safety, tolerability and immunogenicity of investigational Ebola vaccines is conducted in two Parts. In Part 1 subjects are randomized to receive either the cAd3-EBO or cAd3-EBOZ vaccine at two different dose levels. In Part 2, participants from Part 1 may receive a booster injection with the MVA-EbolaZ vaccine; all at the same dose level. The hypotheses are that the study vaccines, cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ, will be safe and will elicit immune responses to Ebola glycoprotein (GP). The primary objectives are to evaluate the safety and tolerability of the study vaccines administered as intramuscular (IM) injections. The secondary objectives are related to immunogenicity.

Study Products Description:

VRC-EBOADC069-00-VP (cAd3-EBO) is composed of two recombinant cAd3 vectors in a 1:1 ratio that express Ebola WT GPs from Zaire and Sudan strains. It is formulated at 2x10(11) particle units (PU)/mL.

VRC-EBOADC076-00-VP (cAd3-EBOZ) is composed of a cAd3 vector that expresses Ebola WT GP from the Zaire strain. It is formulated at 1x10(11) PU/mL.

VRC-DILADC065-00-VP (diluent) is the vaccine formulation buffer and will be used when needed to prepare the correct dosage of cAd3-EBO or cAd3-EBOZ.

VRC-EBOMVA079-00-VP (MVA-EbolaZ) is composed of a MVA vector that expresses Ebola WT GP from the Zaire strain. It is formulated at 3.2x10(8) PFU/mL.

Part 1 Study Plan:

Group 1: 60 volunteers will be randomized: 15 in each of the two dosage groups for VRC-EBOADC069-00-VP [2x10(10) PU or 2x10(11) PU] and 15 in each of the two dosage groups for VRC-EBOADC076-00-VP [1x10(10) PU or 1x10(11) PU].

Group 2: up to 30 volunteers that previously participated in the RV 247 clinical trial who received the investigational product VRC-EBODNA023-00-VP will be randomized to receive one of the two dosage groups for VRC-EBOADC069-00-VP.

The two groups will be enrolled simultaneously. If less then 30 participants enroll into Group 2, additional participants may be enrolled into Group 1 for a total of 90 participants overall. Participants will be evaluated by 9 clinic visits over 48 weeks.

Part 2 Study Plan:

Part 1 participants who received a study vaccination and have completed at least 36 weeks of follow-up, who are eligible and consent may receive a booster injection with the VRC-EBOMVA079-00-VP vaccine at 1x10(8) particle forming units (PFU). Participants will be evaluated by 11 clinic visits over 48 weeks after beginning Part 2.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Phase 1B, Open-Label, Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Investigational Ebola Vaccines, VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP and VRC-EBOMVA079-00-VP in Healthy Adults in Kampala Uganda
Actual Study Start Date : January 27, 2015
Actual Primary Completion Date : April 19, 2017
Actual Study Completion Date : April 19, 2017


Arm Intervention/treatment
Experimental: Group 1a: cAd3-EBOZ at 1x10(10) PU
Part 1: cAd3-EBOZ at 1x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
Biological: cAd3-EBOZ
cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
Other Name: VRC-EBOADC076-00-VP

Biological: MVA-EbolaZ
MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
Other Name: VRC-EBOMVA079-00-VP

Experimental: Group 1b: cAd3-EBOZ at 1x10(11) PU
Part 1: cAd3-EBOZ at 1x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
Biological: cAd3-EBOZ
cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
Other Name: VRC-EBOADC076-00-VP

Biological: MVA-EbolaZ
MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
Other Name: VRC-EBOMVA079-00-VP

Experimental: Group 1c: cAd3-EBO at 2x10(10) PU
Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
Biological: cAd3-EBO
1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each [2x10(11) PU/mL total].
Other Name: VRC-EBOADC069-00-VP

Biological: MVA-EbolaZ
MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
Other Name: VRC-EBOMVA079-00-VP

Experimental: Group 1d: cAd3-EBO at 2x10(11) PU
Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
Biological: cAd3-EBO
1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each [2x10(11) PU/mL total].
Other Name: VRC-EBOADC069-00-VP

Biological: MVA-EbolaZ
MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
Other Name: VRC-EBOMVA079-00-VP

Experimental: Group 2a:cAd3-EBO at 2x10(10) PU
Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
Biological: cAd3-EBO
1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each [2x10(11) PU/mL total].
Other Name: VRC-EBOADC069-00-VP

Biological: MVA-EbolaZ
MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
Other Name: VRC-EBOMVA079-00-VP

Experimental: Group 2b: cAd3-EBO at 2x10(11) PU
Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
Biological: cAd3-EBO
1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each [2x10(11) PU/mL total].
Other Name: VRC-EBOADC069-00-VP

Biological: MVA-EbolaZ
MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
Other Name: VRC-EBOMVA079-00-VP




Primary Outcome Measures :
  1. Incidence of solicited adverse events after vaccination [ Time Frame: 7 days ]
    Incidence is reported for solicited events for 7 days after each vaccination.

  2. Incidence of unsolicited adverse events of any severity 28 days after vaccination [ Time Frame: 28 days ]
    Incidence is reported for unsolicited events for 28 days after each vaccination. The reporting period is Day 0 to Day 28.

  3. Incidence of serious adverse events or new chronic medical conditions through the last study visit [ Time Frame: From first study injection through 48 weeks after final study injection ]
    Incidence is reported of serious adverse events and new chronic medical conditions for 48 weeks after vaccination.

  4. Mean change from baseline in safety laboratory measures [ Time Frame: 28 days after each vaccination ]
    At Days 2 or 3, 14, and 28 blood will be drawn to measure safety measures that many include complete blood count (CBC), creatinine, ALT, PT and PTT.


Secondary Outcome Measures :
  1. Antibody response to Ebola GP as measured by ELISA [ Time Frame: 4 weeks after each vaccination ]
    Blood is collected at baseline and 4 weeks after vaccination

  2. Antibody response to Ebola GP as measured by neutralization assay [ Time Frame: 4 weeks after vaccination ]
    Blood is collected at baseline and 4 weeks after vaccination

  3. T cell immune response measured by intracellular cytokine staining (ICS) [ Time Frame: 4 weeks after vaccination ]
    Blood is collected at baseline and 4 weeks after vaccination



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Part 1 Inclusion Criteria:

A volunteer subject must meet all of the following criteria:

  • 18 to 65 years old.
  • Available for clinical follow-up through Week 48.
  • Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
  • Must be willing to be taken home at enrollment visit and allow home visits if participant does not keep appointments
  • Must complete an Assessment of Understanding successfully.
  • Able to read (English or Luganda) and willing to complete the informed consent process.
  • Willing to donate blood for sample storage to be used for future research.
  • In good general health without clinically significant medical history.
  • Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) ≤ 40 within the 56 days prior to enrollment.

Laboratory Inclusion Criteria within 56 days prior to enrollment:

  • Hemoglobin ≥ 11.0 g/dL for women; ≥12.5 g/dL for men.
  • White blood cells (WBC) = 2,500-12,000 cells/mm3.
  • WBC differential either within institutional normal range or accompanied by the Principal Investigator (PI) or designee approval.
  • Total lymphocyte count ≥ 800 cells/mm3.
  • Platelets = 125,000 - 400,000/mm3.
  • Alanine aminotransferase (ALT) ≤ 1.25 x upper limit of normal (ULN).
  • Serum creatinine ≤ 1 x ULN.
  • Partial thromboplastin time (PTT) within institutional normal range.
  • Prothrombin time (PT) within institutional normal range.
  • HIV-uninfected as evidenced by a negative FDA-approved HIV diagnostic test.

Female-Specific Inclusion Criteria:

  • Negative β-HCG (human chorionic gonadotropin) pregnancy test on day of enrollment.
  • Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 24 weeks after study vaccination if presumed to be of reproductive potential.

Part 1 Exclusion Criteria:

Volunteer has received any of the following substances:

  • Investigational Ebola or Marburg vaccine (other than the Ebola DNA vaccine delivered in RV 247) in a prior clinical trial or prior receipt of a cAd3 adenoviral vectored investigational vaccine.
  • Chronic use of immunomodulators and systemic glucocorticoids in daily doses of glucocorticoid equivalence > 20 mg of prednisolone, for periods exceeding 10 days. Non-steroidal anti-inflammatory drugs [NSAIDS] are permitted.
  • Participants that have used less than the stated glucocorticoid dose may still be excluded at the Investigator's discretion.
  • Blood products within 112 days prior to enrollment.
  • Investigational research agents within 28 days prior to enrollment.
  • Live attenuated vaccines within 28 days prior to enrollment.
  • Subunit or killed vaccines within 14 days prior to enrollment.
  • Current anti-tuberculosis prophylaxis or therapy.

Female-Specific Exclusion Criteria:

  • Woman who is breast-feeding or planning to become pregnant during the first 24 weeks after study vaccine administration.

Volunteer has a history of any of the following clinically significant conditions:

  • Serious adverse reactions to vaccines such as anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain.
  • Clinically significant autoimmune disease or immunodeficiency.
  • Asthma that is not well controlled.
  • Diabetes mellitus (type I or II), with the exception of gestational diabetes.
  • Thyroid disease that is not well controlled.
  • A history of hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema.
  • Idiopathic urticaria within the last 1 year.
  • Hypertension that is not well controlled.
  • Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.
  • Malignancy that is active or history of a malignancy that is likely to recur during the period of the study.
  • Seizure in the past 3 years or treatment for seizure disorder in the past 3 years.
  • Asplenia or functional asplenia.
  • Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within five years prior to enrollment, history of a suicide plan or attempt.
  • Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.

Part 2 Inclusion Criteria:

  • Received the Part 1 study injection and is willing to participate in Part 2.
  • Satisfactory completion of the Assessment of Understanding
  • Subject is assessed by the Site Principal Investigator or designee as in good general health without clinically significant medical history that precludes participation.

Female-Specific Inclusion Criteria:

  • Negative β-HCG pregnancy test on day of enrollment if presumed to be of reproductive potential.
  • Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 24 weeks after study vaccination if presumed to be of reproductive potential.

Part 2 Exclusion Criteria:

  • Type 1 hypersensitivity to aminoglycosides antibiotics.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02354404


Locations
Layout table for location information
Uganda
Makerere University Walter Reed Project
Kampala, Uganda
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
US Military HIV Research Program
The Emmes Company, LLC
Investigators
Layout table for investigator information
Study Chair: Merlin Robb, MD US Military HIV Research Program
Study Chair: Julie Ledgerwood, DO VRC, NIAID, NIH
Publications:
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT02354404    
Other Study ID Numbers: RV 422
First Posted: February 3, 2015    Key Record Dates
Last Update Posted: December 5, 2017
Last Verified: September 2017
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Ebola virus
Filoviridae Infections
Hemorrhagic Fever, Ebola
Viral Diseases
Hemorrhagic Fevers, Viral
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemorrhagic Fever, Ebola
Hemorrhagic Fevers, Viral
RNA Virus Infections
Virus Diseases
Filoviridae Infections
Mononegavirales Infections